Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
STOK 
Stoke Therapeutics Inc (STOK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/01/2025: STOK (5-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $31.62
1 Year Target Price $31.62
| 7 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 74.87% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.72B USD | Price to earnings Ratio 44.25 | 1Y Target Price 31.62 |
Price to earnings Ratio 44.25 | 1Y Target Price 31.62 | ||
Volume (30-day avg) 10 | Beta 1.14 | 52 Weeks Range 5.35 - 38.69 | Updated Date 12/2/2025 |
52 Weeks Range 5.35 - 38.69 | Updated Date 12/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.68 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-11-11 | When - | Estimate -0.5805 | Actual -0.65 |
Profitability
Profit Margin 19.73% | Operating Margin (TTM) -405.3% |
Management Effectiveness
Return on Assets (TTM) 5.2% | Return on Equity (TTM) 15.02% |
Valuation
Trailing PE 44.25 | Forward PE 204.08 | Enterprise Value 1520089106 | Price to Sales(TTM) 8.36 |
Enterprise Value 1520089106 | Price to Sales(TTM) 8.36 | ||
Enterprise Value to Revenue 7.39 | Enterprise Value to EBITDA 52.26 | Shares Outstanding 57117150 | Shares Floating 40841047 |
Shares Outstanding 57117150 | Shares Floating 40841047 | ||
Percent Insiders 9.6 | Percent Institutions 119.38 |
Upturn AI SWOT
Stoke Therapeutics Inc
Company Overview
History and Background
Stoke Therapeutics, Inc. was founded in 2014 and is a biotechnology company pioneering a new approach to treat genetic diseases by precisely upregulating protein expression. Their initial focus is on treating genetic epilepsies.
Core Business Areas
- RNA-based medicines: Stoke Therapeutics develops RNA-based medicines that target the underlying cause of severe genetic diseases by increasing protein production from healthy genes.
- Genetic Epilepsy Therapies: The company's lead product candidate is focused on Dravet syndrome, a severe form of epilepsy.
Leadership and Structure
Edward M. Kaye, M.D. is the Chief Executive Officer of Stoke Therapeutics. The company has a board of directors comprising experienced individuals from the biotechnology and pharmaceutical industries.
Top Products and Market Share
Key Offerings
- STK-001 (Dravet Syndrome): STK-001 is an antisense oligonucleotide (ASO) being developed for the treatment of Dravet syndrome. It aims to upregulate the expression of the SCN1A gene. The potential market size for Dravet Syndrome therapies is significant, but market share is currently undefined as STK-001 is in clinical trials. Competitors include Zogenix (acquired by UCB) (FINTEPLA), Biocodex (DIACOMIT), and GW Pharmaceuticals (acquired by Jazz Pharmaceuticals) (EPIDIOLEX).
Market Dynamics
Industry Overview
The biotechnology industry is characterized by rapid innovation, high R&D costs, and stringent regulatory requirements. Gene therapies and RNA-based therapeutics are a growing area of focus.
Positioning
Stoke Therapeutics is positioned as a leader in the development of RNA-based medicines for genetic diseases, particularly those with haploinsufficiency (where one copy of a gene is non-functional). Their focus on upregulation differentiates them from gene editing approaches.
Total Addressable Market (TAM)
The global market for genetic therapies is estimated to reach billions of dollars. Stoke Therapeutics is targeting specific genetic diseases with high unmet needs. The exact TAM for Stoke's pipeline is dependent on clinical success and regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel RNA-based technology
- Strong intellectual property position
- Experienced management team
- Targeting diseases with high unmet medical need
Weaknesses
- Clinical trial risk
- High R&D expenses
- Reliance on single lead product candidate
- Relatively small market capitalization
Opportunities
- Expansion of pipeline to other genetic diseases
- Potential for partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Regulatory approval of STK-001
Threats
- Competition from other gene therapy companies
- Adverse clinical trial results
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- UCB (UCBJF)
- Jazz Pharmaceuticals (JAZZ)
- Encoded Therapeutics (Private)
- Neurogene (Private)
Competitive Landscape
Stoke competes with companies developing therapies for genetic epilepsies and other genetic diseases. Its RNA-based approach offers a unique mechanism of action, but carries inherent risks associated with novel technologies. Market shares of specific therapies for Dravet Syndrome are difficult to quantify precisely.
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily driven by advancement of clinical trials and pipeline development. Significant revenue is contingent upon product approval.
Future Projections: Future growth depends on clinical trial outcomes, regulatory approvals, and commercialization success. Analyst estimates vary widely.
Recent Initiatives: Advancing STK-001 through clinical trials, expanding research efforts to identify new targets, and exploring potential partnerships.
Summary
Stoke Therapeutics is a biotechnology company focused on RNA-based therapies for genetic diseases, particularly Dravet Syndrome. Their lead product candidate, STK-001, is in clinical trials and represents a significant potential opportunity. However, the company faces the risks inherent in drug development, including clinical trial outcomes and regulatory hurdles. Success is highly dependent on the clinical success of STK-001 and expansion of their pipeline.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Stoke Therapeutics Investor Relations
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. The information provided is based on publicly available data and may not be exhaustive. Investment decisions should be made based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Stoke Therapeutics Inc
Exchange NASDAQ | Headquaters Bedford, MA, United States | ||
IPO Launch date 2019-06-19 | CEO & Director Mr. Ian F. Smith A.C.A., C.P.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 128 | |
Full time employees 128 | |||
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase I/II clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.